Trials / Sponsors / Ze-yang Ding, MD
Ze-yang Ding, MD
Academic / Other · 2 registered clinical trials — 1 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Unknown | DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma Cholangiocarcinoma Non-resectable | — | 2022-02-01 |
| Recruiting | Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma Hepatocellular Carcinoma Non-resectable | — | 2020-05-19 |